Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 17/20 | 0.55 |
| ▸ | CIT | O14578 | 1/20 | 0.46 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.46 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.46 |
| ▸ | STK10 | O94804 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | RAF1 | P04049 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | CSF1R | P07333 | 1/20 | 0.46 |
| ▸ | YES1 | P07947 | 1/20 | 0.46 |
| ▸ | LYN | P07948 | 1/20 | 0.46 |
| ▸ | RET | P07949 | 1/20 | 0.46 |
| ▸ | HCK | P08631 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | FGR | P09769 | 1/20 | 0.46 |
| ▸ | KIT | P10721 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5176609 | 0.90 | KDR (0.50) | KDRCITMAP3K7RIPK2STK10 | |
| SCHEMBL5176604 | 0.89 | KDR (0.49) | KDRCITMAP3K7RIPK2STK10 | |
| SCHEMBL1490859 | 0.86 | KIT (0.50) | KDRCITMAP3K7RIPK2STK10 | |
| SCHEMBL1490758 | 0.86 | KDR (0.47) | KDRCITMAP3K7RIPK2STK10 | |
| SCHEMBL1493301 | 0.83 | KDR (0.45) | KDRCITMAP3K7RIPK2STK10 | |
| SCHEMBL1490345 | 0.82 | ABCB1 (0.51) | KDRCITMAP3K7RIPK2STK10 | |
| SCHEMBL1490691 | 0.81 | KDR (0.45) | KDRCITMAP3K7RIPK2STK10 | |
| SCHEMBL427718 | 0.79 | KDR (0.62) | KDRCITMAP3K7RIPK2STK10 | |
| SCHEMBL3873766 | 0.78 | KIT (0.59) | KDRKITBRAFFLT1NOTUM | |
| SCHEMBL1488991 | 0.78 | NOTUM (0.48) | KDRKITBRAFFLT1NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1807416-B1 | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors | Bayer Pharma AG (DE) | 2012-08-29 | — | — | EP | disclosed |
| EP-1807416-B1 | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors | Bayer Pharma AG (DE) | 2012-08-29 | — | — | EP | disclosed |
| US-7906533-B2 | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors | BAYER SCHERING PHARMA AG (DE) | 2011-03-15 | — | — | US | disclosed |
| US-7906533-B2 | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors | BAYER SCHERING PHARMA AG (DE) | 2011-03-15 | — | — | US | disclosed |
| US-7906533-B2 | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors | BAYER SCHERING PHARMA AG (DE) | 2011-03-15 | — | — | US | disclosed |
| CN-101056870-A | Nicotinamide pyridinureas as vascular endothelial growth factor (vegf) receptor kinase inhibitors | BAYER SCHERING PHARMA AG (DE) | 2007-10-17 | — | — | CN | disclosed |
| EP-1807416-A1 | NICOTINAMIDE PYRIDINUREAS AS VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) RECEPTOR KINASE INHIBITORS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-07-18 | — | — | EP | disclosed |
| US-20060160861-A1 | Novel nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2006-07-20 | — | — | US | disclosed |
| WO-2006048249-A1 | NICOTINAMIDE PYRIDINUREAS AS VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) RECEPTOR KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160861-A1 | Novel nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors | FLT1, KDR, FLT4 | KDR 2/4885CIT 1975/4885MAP3K7 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.